Medication–those of us with Metastatic Breast Cancer (MBC), we take a LOT of medication, every day. Sometimes, we have no choice as to the modality or location the medication is taken. Some examples of the modality are: 1) pill; 2) injection; or 3) infusion. Some examples of location are: 1) home; 2) doctor’s office; 3) clinic; 4) infusion center; 5) in the hospital.
And what about co-pays? Adiba talks about that ….
Being terminally ill is complicated. The medication is complicated. The insurance issues are complicated. The result of these complicates our ability to rest and increases our stress exponentially. Add in unscrupulous vendors and the aggressiveness of collection agencies and it can be brutal.
Enter a solution: HB1730 and SB741, the Cancer Drug Parity Act. This Bill would help every single cancer patient in that it says that the patient’s co-pay is the same for the medication regardless of modality or location. I’m fully aware that the health insurance and pharmaceutical companies have strong lobbyist and they speak up, loudly. Yet, I also believe that every single person has an obligation to look at this situation as they would care for the members of their own family: would my mom/sister/grandmother/grandfather/father/brother be able to figure this out while handling a terminal illness?
Even if the answer is yes, why should a terminally ill person have to deal with this amount of stress? It’s a legitimate question that I believe should be posed to each and every person in the industry. Why are we putting stress on those least able to handle it?
Here’s another reason — after I went through chemo, I struggled with word recall, I struggled to retain information that I’d read and so I took a neuropsychological test. It demonstrated that I’d lost 20 IQ points.
20 IQ points was the demonstrable damage to my brain from chemo and that was about a year after I’d finished chemo.
Mahatma Ghandi or Hubert Humphrey (or maybe both) said — “The true measure of any society can be found in how it treats its most vulnerable members.”
How are we treating the dying in our society?
And now you know more about what would help vulnerable, terminal patents.